BioNTech SE

AI-generated fair value estimate for this company.

Method: Sum-of-the-parts rather than a single DCF: about $14.6B net cash (negligible debt); a 10-year DCF on the core commercial/infectious-disease franchise using a roughly $2.0B normalized revenue base, 20% FCF margin, 10% discount rate and 2% terminal growth, worth about $4.3B; plus a risk-adjusted oncology pipeline NPV of about $6.0B anchored to the BNT327/pumitamig partnership worth up to $11.1B in payments; 251.2M shares outstanding.

Reasoning: BNTX's current thin, volatile cash flow badly understates the business, which is dominated by a large net-cash pile and optionality on an unapproved but well-funded oncology pipeline, so cash plus core-business DCF plus risk-adjusted pipeline NPV better captures intrinsic value than a plain DCF.